US firm Sonus Pharmaceuticals and Vancouver, Canada-headquartered OncoGenex Technologies are to merge. The combined company will operate as OncoGenex Pharmaceuticals and Scott Cormack will continue as president and chief executive. The new company's lead candidate is OGX-11, a clusterin- inhibitor to restrict treatment resistance for solid tumors. The candidate is currently undergoing five Phase II clinical trials, each of which has completed patient enrollment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze